Neurology · 2001 · 26 citations · 6 references
MedicineGeneticsOncologyCancer GeneticsMolecular OncologyOncogenesHereditary HemochromatosisIron Chelation TherapyIron DeficiencyIron HomeostasisIron MetabolismOncogene MutationsHemochromatosis PathophysiologyHfe Gene MutationsIron Homeostasis RegulationIron Metabolism GeneticsIron Overload PathophysiologyMutationMyc Proto-oncogeneNon-heme Iron Metabolism
Risk factors for brain tumors, except for ionizing radiations, remain substantially unknown.1 Iron exposure could be among these factors, as in vitro iron may promote the growth of malignant gliomas2 and iron chelators can inhibit this growth.3 Excess iron can favor the generation of highly reactive hydroxyl radicals, which, in turn, may cause point mutations in genomic DNA. Furthermore, increased levels of non-heme iron can convert nitric oxide from a proapoptotic to an antiapoptotic molecule. Notably, the c-myc oncogene, which is also expressed in high-grade gliomas, modulates the expression of genes controlling iron homeostasis, increasing the availability of intracellular iron.4 The hereditary hemochromatosis gene ( HFE ) has a critical role in iron homeostasis and two mutations of this gene, C282Y and H63D, are …
6
A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis
John N. Feder, Andreas Gnirke, Zenta Tsuchihashi et al. · Nature Genetics · 1996 · 3.7K citations